Skip to Content

News Release

Media Contact: Tom Grant

Published on May 02, 2003

Press Release

New Cardiac Device Now Available for Heart Disease Patients

Drug-Coated Stents Proven to Help Prevent Re-growth of Diseased Tissue

Takoma Park, MD - Doctors at Washington Adventist Hospital are now implanting drug-coated stents in heart disease patients receiving an angioplasty procedure.

Clinical trials have shown that the drug-coated stent, known as the CYPHER stent and developed by the Cordis Corporation, is effective in preventing re-growth of diseased tissue after a blocked coronary artery has been opened.

Doctors at Washington Adventist Hospital already have performed more than 20 angioplasty procedures using this new stent since its commercial approval by the Food and Drug Administration (FDA). The hospital was one of the first in the region to make this device available to patients since its commercial approval.

"This device is a revolutionary advancement in cardiology medicine," said Mark Turco, M.D., Director of the Center for Cardiovascular Research at Washington Adventist Hospital. "The drug coated stent dramatically improves the effectiveness of angioplasty procedures and may help many heart disease patients avoid having open-heart surgery or a repeat angioplasty procedure."

Each year some 750,000 angioplasty procedures are performed to open blocked arteries in patients with heart disease. During angioplasty, a doctor inflates a balloon inside the artery to open the passageway, and in many cases a stent - a tiny mesh tube - is inserted to help keep the artery propped open.

While stents have proven effective, in some cases tissue grows again at the diseased site and clogs both the artery and the stent. This re-growth of tissue, known as restenosis, requires either an additional angioplasty procedure or open-heart surgery.

The CYPHER stent is coated with Rapamune, a drug initially developed for organ transplant patients, and after the physician implants the stent at the diseased site the medicine is slowly released over a period of approximately 30 days. The release of the medicine is highly localized and causes no adverse impact on the patient.

Some 62 million Americans have a form of cardiovascular disease, the leading cause of death according to the American Heart Association.

Washington Adventist Hospital, located in Takoma Park, Maryland, is a 327-bed hospital that has offered leading edge cardiology care to tens of thousands of patients throughout the East Coast for more than 30 years. The Center for Cardiac & Vascular Research, led by Dr. Turco, coordinates the hospital's involvement in various clinical trials and research projects.

Get Social. Get Involved. Be Heard!

Join us on the social Web to learn more about Adventist HealthCare doctors, programs and specialized services:

AHC&You Blog | @AdventistHC | Facebook | YouTube

News & Media Coverage

Local Health News - In Your Inbox

Join over 40k of your friends & neighbors and get the latest news about community health programs and events when you sign-up for Adventist HealthCare & You Digital.

Subscribe Today!